Basic Information
Brimica Genuair
Regulatory Information
EMEA/H/C/003969
November 19, 2014
16
June 20, 2024
Company Information
the netherlands
Gustav Mahlerplein 2 1082 MA Amsterdam
Covis Pharma Europe BV
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Brimica Genuair is indicated as a maintenance bronchodilator treatment for airflow obstruction and relief of symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Overview Summary
This is a summary of the European public assessment report (EPAR) for Brimica Genuair. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Brimica Genuair. For practical information about using Brimica Genuair, patients should read the package leaflet or contact their doctor or pharmacist.